ArticleJACC. Case reports2025
Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis With High Surgical Risk.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early Experience With the Septal Scoring Along the Midline Endocardium (SESAME) Technique in the Asia-Pacific Region.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreatment and accurate assessment of aortic valve stenosis (AS) with concomitant obstructive hypertrophic cardiomyopathy (HCM) prove challenging. CASE SUMMARY: We present a case series of 6 patients with obstructive HCM and severe AS who underwent alcohol septal ablation (ASA) and follow-up reassessment of AS severity. AS severity was downgraded in 3 of 6 cases. One patient had residual obstruction necessitating mavacamten before transcatheter aortic valve replacement (TAVR). TAVR was performed in 2 of 6 cases. DISCUSSION: Doppler assessment of AS is technically challenging in HCM. A staged intervention with ASA and/or mavacamten before TAVR requires thoughtful consideration. The literature supports the use of ASA in a staged fashion before TAVR. Limited data are published on the use of mavacamten before TAVR. TAKE-HOME MESSAGES: ASA and mavacamten are effective means to relieve obstruction in patients with concomitant severe AS. The benefit is 2-fold: 1) this approach provides more accurate Doppler assessment of AS severity; and 2) it reduces the likelihood of complications during TAVR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.